Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sharper scans during radiation: a pilot study

NCT ID NCT07219134

Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new type of CT scan (dual energy CT) can produce clearer images of tumors during radiation therapy. Researchers compared the new scan to the standard scan in 30 adults receiving radiation for pelvic or genitourinary cancers. The goal was to see if the new method improves image quality, which could help doctors target tumors more accurately.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this imaging technique could help doctors see tumors more clearly during radiation, potentially leading to more precise treatments.
What could go wrong
This was a small pilot study with only 30 participants, focused on image quality rather than patient outcomes. The technique may not improve treatment results in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Jun 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with pelvis or genitourinary cancer requiring standard of care radiotherapy treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \* Patients with pelvis or genitourinary (GU) cancer requiring standard of care radiotherapy treatment * All adults, defined as individuals of 18 years of age or greater * Radiotherapy treatment will be performed on the Varian Ethos radiotherapy system * Ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * \* Minors, defined as individuals less than 18 years of age * Pregnant or nursing female

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genitourinary system carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant urinary system neoplasm Pelvic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genitourinary system carcinoma Malignant pelvic neoplasm

Contacts and locations

Locations

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.